Additionally, SLC7A11 influences the immune response to therapy by regulating the redox balance and immune cell infiltration (such as inhibiting CD8+ T cell activity) in the tumor microenvironment, and its expression is subject to multi-level regulation by epigenetic modifications (such as m6A, ubiquitination) and transcription factors (NRF2, ATF4), offering diverse targets for the development of small molecule inhibitors, metabolic interventions (glucose deprivation), or combination therapies (such as with immune checkpoint inhibitors). The gene discussed is ATF4; the disease is neoplasm.